The incidence of hypoglycemia, which is an important component of safety, increased significantly with addition of sulfonylureas, glinides, or insulin, but did not increase significantly with alfa-glucosidase, DPP4 or SGLT2 inhibitors, GLP1 agonists, or thiazolidinediones 39-41. This evidence concerns the gene SLC5A2 and Hypoglycemia.